Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000628 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
A Phase 1 study of HIV Infections, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 5
- Study locations
NCT00000628 is a Phase 1 study of HIV Infections that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 27 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00000628, a Phase 1 study of HIV Infections, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 5
- Study locations
Study Summary
Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To begin a study of the antiviral activity of L-697,661. L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and growth) in cell culture. It works together with AZT against HIV.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG L-697,661
Study Locations (5)
Illinois
- Northwestern Univ Med School - Chicago
- Rush Presbyterian - Saint Luke's Med Ctr - Chicago
California
- San Francisco Gen Hosp - San Francisco
Colorado
- Univ of Colorado Health Ctr / Denver Gen Hosp - Denver
Washington
- Univ of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000628
The ClinicalTrials.gov registry entry for NCT00000628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00000628 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Illinois, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00000628 about?
NCT00000628 is a clinical study titled "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine". Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To begin a study of the antiviral activit...
What is the current status of trial NCT00000628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants.
What conditions does trial NCT00000628 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000628?
The interventions under investigation include: Zidovudine (DRUG), L-697,661 (DRUG).
Who is sponsoring clinical trial NCT00000628?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000628 being conducted?
This trial has 5 study locations across California, Colorado, Illinois, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.